|
000
| 01851nam 2200301za 4500 |
|---|
| 001 | 9.847591 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20221107153457 |
|---|
| 007 | cr ||||||||||| |
|---|
| 008 | 171122s2018 onca o f000 0 eng d |
|---|
| 020 | |a9780660239675|z9780660239682 |
|---|
| 040 | |aCaOODSP|beng |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aNR16-176/2017E-PDF |
|---|
| 245 | 00|aSalmonella vector (L-12259) |h[electronic resource]. |
|---|
| 260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
|---|
| 300 | |a[1] p. : |bill. |
|---|
| 500 | |aIssued also in French under title: Vecteur de vaccin à base de salmonelle (L-12259). |
|---|
| 500 | |aCaption title. |
|---|
| 500 | |a"December 2017." |
|---|
| 520 | |a“Promising approaches for delivering antigens and generating a protective response against cancers and infectious diseases currently employ existing vaccine strain bacteria or closely-related attenuated bacteria. Human clinical trials have shown excellent safety profiles with various recombinant vaccine strain bacteria, but generally poor efficacies for promoting immunity against the targeted diseases. Finding the right vaccine vector and antigen production system to rapidly induce an immune response while causing minimal toxicity has been challenging. To address this problem, the NRC has developed a recombinant attenuated Salmonella vaccine system capable of producing rapid cell-mediated immune protection against infectious diseases and cancers”--Highlights. |
|---|
| 530 | |aIssued also in print format. |
|---|
| 693 | 4|aDrug delivery systems |
|---|
| 693 | 4|aSalmonella |
|---|
| 710 | 2 |aNational Research Council Canada. |
|---|
| 775 | 08|tVecteur de vaccin à base de salmonelle (L-12259) |w(CaOODSP)9.847593 |
|---|
| 776 | 0#|tSalmonella vector |w(CaOODSP)9.847592 |
|---|
| 856 | 40|qPDF|s138 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-176-2017-eng.pdf |
|---|